Moderna's recent stumbles make the company an acquisition target. Merck desperately needs Moderna's mRNA-based Personal Cancer Vaccines ("PCVs") to extend KEYTRUDA's patent protection beyond 2028.
ASML Holdings N.V. experienced a sharp decline due to lowered Q3 guidance but has shown signs of bottoming out with positive momentum indicators. Technical analysis reveals oversold conditions, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback